Identification of Three Classes of Heteroaromatic Compounds with Activity Against Intracellular Trypanosoma Cruzi by Chemical Library Screening

Overview

Journal PLoS Negl Trop Dis

Specialties Infectious Diseases
Tropical Medicine

Date 2009 Feb 25

PMID 19238193

Citations 39

Authors

Esther Bettiol

Marie Samanovic

Andrew S Murkin

Jayne Raper

Frederick Buckner

Ana Rodriguez

Affiliations

Soon will be listed here.

Abstract

The development of new drugs against Chagas disease is a priority since the currently available medicines have toxic effects, partial efficacy and are targeted against the acute phase of disease. At present, there is no drug to treat the chronic stage. In this study, we have optimized a whole cell-based assay for high throughput screening of compounds that inhibit infection of mammalian cells by Trypanosoma cruzi trypomastigotes. A 2000-compound chemical library was screened using a recombinant T. cruzi (Tulahuen strain) expressing beta-galactosidase. Three hits were selected for their high activity against T. cruzi and low toxicity to host cells in vitro: PCH1, NT1 and CX1 (IC(50): 54, 190 and 23 nM, respectively). Each of these three compounds presents a different mechanism of action on intracellular proliferation of T. cruzi amastigotes. CX1 shows strong trypanocidal activity, an essential characteristic for the development of drugs against the chronic stage of Chagas disease where parasites are found intracellular in a quiescent stage. NT1 has a trypanostatic effect, while PCH1 affects parasite division. The three compounds also show high activity against intracellular T. cruzi from the Y strain and against the related kinetoplastid species Leishmania major and L. amazonensis. Characterization of the anti-T. cruzi activity of molecules chemically related to the three library hits allowed the selection of two compounds with IC(50) values of 2 nM (PCH6 and CX2). These values are approximately 100 times lower than those of the medicines used in patients against T. cruzi. These results provide new candidate molecules for the development of treatments against Chagas disease and leishmaniasis.

Citing Articles

Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models.

Soeiro M, Sales-Junior P, Alves Pereira V, Vannier-Santos M, Murta S, Silvestre de Sousa A Mem Inst Oswaldo Cruz. 2024; 119:e240057.

PMID: 38958341 PMC: 11218046. DOI: 10.1590/0074-02760240057.

State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation.

Gabaldon-Figueira J, Martinez-Peinado N, Escabia E, Ros-Lucas A, Chatelain E, Scandale I Res Rep Trop Med. 2023; 14:1-19.

PMID: 37337597 PMC: 10277022. DOI: 10.2147/RRTM.S415273.

High growth hormone serum partially protects mice against Trypanosoma cruzi infection.

Mora-Criollo P, Basu R, Qian Y, Funk K, Bell S, Young J FEBS Open Bio. 2023; 13(7):1346-1356.

PMID: 37163287 PMC: 10315831. DOI: 10.1002/2211-5463.13627.

Exploring Synthetic Dihydrobenzofuran and Benzofuran Neolignans as Antiprotozoal Agents against .

Pagotti M, Dias H, Candido A, Oliveira T, Borges A, Oliveira N Pharmaceutics. 2023; 15(3).

PMID: 36986617 PMC: 10052957. DOI: 10.3390/pharmaceutics15030754.

Anti-Trypanosoma cruzi activity of Coptis rhizome extract and its constituents.

Tayama Y, Mizukami S, Toume K, Komatsu K, Yanagi T, Nara T Trop Med Health. 2023; 51(1):12.

PMID: 36859380 PMC: 9976467. DOI: 10.1186/s41182-023-00502-2.

References

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M . New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis. 2008; 47(8):1000-6. DOI: 10.1086/591972. View

SEEBER F, Boothroyd J . Escherichia coli beta-galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii. Gene. 1996; 169(1):39-45. DOI: 10.1016/0378-1119(95)00786-5. View

Finlayson K, Witchel H, McCulloch J, Sharkey J . Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol. 2004; 500(1-3):129-42. DOI: 10.1016/j.ejphar.2004.07.019. View

Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling R . Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol. 2007; 5(11):873-82. DOI: 10.1038/nrmicro1748. View

Vega C, Rolon M, Martinez-Fernandez A, Escario J, Gomez-Barrio A . A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase. Parasitol Res. 2005; 95(4):296-8. DOI: 10.1007/s00436-005-1300-3. View

Baum S, Wittner M, Nadler J, Horwitz S, Dennis J, Schiff P . Taxol, a microtubule stabilizing agent, blocks the replication of Trypanosoma cruzi. Proc Natl Acad Sci U S A. 1981; 78(7):4571-5. PMC: 319834. DOI: 10.1073/pnas.78.7.4571. View

Spath G, Beverley S . A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp Parasitol. 2001; 99(2):97-103. DOI: 10.1006/expr.2001.4656. View

Mersch-Sundermann V, Knasmuller S, Wu X, Darroudi F, Kassie F . Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents. Toxicology. 2004; 198(1-3):329-40. DOI: 10.1016/j.tox.2004.02.009. View

Silva R, Hall B, Joiner K, Sacks D . CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J Immunol. 1989; 143(2):617-22. View

10.

Grellier P, Sinou V, Bylen E, Boulard Y, Schrevel J . Selective and reversible effects of vinca alkaloids on Trypanosoma cruzi epimastigote forms: blockage of cytokinesis without inhibition of the organelle duplication. Cell Motil Cytoskeleton. 1999; 42(1):36-47. DOI: 10.1002/(SICI)1097-0169(1999)42:1<36::AID-CM4>3.0.CO;2-G. View

11.

Kao R, Jenkins J, Olson K, Key M, Fett J, Shapiro R . A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc Natl Acad Sci U S A. 2002; 99(15):10066-71. PMC: 126625. DOI: 10.1073/pnas.152342999. View

12.

Kapler G, Coburn C, Beverley S . Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression. Mol Cell Biol. 1990; 10(3):1084-94. PMC: 360971. DOI: 10.1128/mcb.10.3.1084-1094.1990. View

13.

Blair I, Mansilla Tinoco R, Brodie M, Clare R, Dollery C, Timbrell J . Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Hum Toxicol. 1985; 4(2):195-202. DOI: 10.1177/096032718500400210. View

14.

Zhang , Chung , OLDENBURG . A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 2000; 4(2):67-73. DOI: 10.1177/108705719900400206. View

15.

Nair R, Avila H, Ma X, Wang Z, Lennartz M, Darnay B . A novel high-throughput screening system identifies a small molecule repressive for matrix metalloproteinase-9 expression. Mol Pharmacol. 2007; 73(3):919-29. DOI: 10.1124/mol.107.042606. View

16.

McFadden D, SEEBER F, Boothroyd J . Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob Agents Chemother. 1997; 41(9):1849-53. PMC: 164023. DOI: 10.1128/AAC.41.9.1849. View

17.

Mosser D, Edelson P . The third component of complement (C3) is responsible for the intracellular survival of Leishmania major. Nature. 1987; 327(6120):329-31. DOI: 10.1038/327329b0. View

18.

Buckner F, Verlinde C, La Flamme A, Van Voorhis W . Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother. 1996; 40(11):2592-7. PMC: 163582. DOI: 10.1128/AAC.40.11.2592. View

19.

De Souza W . Basic cell biology of Trypanosoma cruzi. Curr Pharm Des. 2002; 8(4):269-85. DOI: 10.2174/1381612023396276. View

20.

Castro J, Montalto de Mecca M, Bartel L . Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol. 2006; 25(8):471-9. DOI: 10.1191/0960327106het653oa. View